ReviewWound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society
Anacaulase-Bcdb for Enzymatic Eschar Removal in Adult and Paediatric Thermal Burns: Clinical Evidence, Safety, and Therapeutic Positioning.
Review in Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep partial-thickness and full-thickness thermal burns require timely eschar removal, but surgical excision can sacrifice viable dermis, cause blood loss, and consume operating-room resources. Anacaulase-bcdb is a standardised pineapple stem-derived proteolytic biologic approved for enzymatic eschar removal in eligible adult and paediatric thermal burns. This Drug Evaluation reviews the product's biological origin, composition, mechanism of action, regulatory status, administration, clinical efficacy, safety and place in therapy. A targeted review of peer-reviewed and regulatory evidence was undertaken, prioritising the phase 3 DETECT trial, the randomised paediatric CIDS trial, systematic reviews, consensus guidance, prescribing information, and postmarketing studies. Anacaulase-bcdb provides rapid eschar removal, reduces surgical excision and debridement-related blood loss, and preserves subsequent options for conservative healing or grafting. Procedural pain, hypersensitivity, strict eligibility criteria, and specialist-team requirements remain important limitations. Anacaulase-bcdb is a clinically meaningful, tissue-sparing adjunct rather than a replacement for burn surgery. Its greatest value is likely in eligible deep partial-thickness and selected full-thickness thermal burns treated within protocolized burn-center pathways. Future adoption will depend on comparative effectiveness, cost-effectiveness, real-world safety, optimal patient selection and evidence that reduced operative burden translates into improved clinical and health-system outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.